SCHEMBL8736952

SCHEMBL8736952

CCCCCCCCCCCCC/C=C\[C@@H](O)[C@@H](N)COP(=O)(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 1.00
S1PR4 O95977 2/20 1.00
S1PR3 Q99500 2/20 1.00
S1PR5 Q9H228 2/20 1.00
ALDH1A1 P00352 2/20 1.00
S1PR2 O95136 1/20 1.00
TSPO P30536 1/20 1.00
TMEM97 Q5BJF2 1/20 1.00
SIGMAR1 Q99720 1/20 1.00
SGPL1 O95470 4/20 0.65
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
PLA2G4A P47712 3/20 0.61
MAPT P10636 3/20 0.60
GMNN O75496 2/20 0.60
LMNA P02545 2/20 0.60
GLA P06280 2/20 0.60
POLB P06746 2/20 0.60
THRB P10828 2/20 0.60
CETP P11597 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438139 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL17482409 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL12766764 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL6055753 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL2561998 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL3517452 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL3885 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL22910837 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL20798182 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1
SCHEMBL29963390 1.00 S1PR1 (1.00) S1PR1S1PR4S1PR3S1PR5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170114125-A1 METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY INTERNATIONAL, LLC 2017-04-27 US disclosed
US-20170114125-A1 METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY INTERNATIONAL, LLC 2017-04-27 US disclosed
US-20170088634-A1 TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2017-03-30 US disclosed
US-20170088634-A1 TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2017-03-30 US disclosed
US-20160168270-A1 PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-06-16 US disclosed
US-20160152735-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-06-02 US disclosed
US-20160152735-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-06-02 US disclosed
US-20160146844-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-05-26 US disclosed
US-20160075775-A1 TREATMENT OF TRAUMATIC BRAIN INJURY USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID APOLLO ENDOSURGERY, INC. 2016-03-17 US disclosed
US-9274129-B2 Methods and reagents for detecting bioactive lipids LPATH, INC. (US) 2016-03-01 US disclosed
US-20090074720-A1 METHODS FOR DECREASING IMMUNE RESPONSE AND TREATING IMMUNE CONDITIONS SABBADINI ROGER A 2009-03-19 US disclosed
US-20080213274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE LPATH, INC. 2008-09-04 US disclosed
US-20080213274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE LPATH, INC. 2008-09-04 US disclosed
US-20080145360-A1 Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders INNOVATUS LIFE SCIENCES LENDING FUND I, LP 2008-06-19 US disclosed
US-20080145360-A1 Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders INNOVATUS LIFE SCIENCES LENDING FUND I, LP 2008-06-19 US disclosed
US-20080138334-A1 Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same SABBADINI ROGER A 2008-06-12 US disclosed
US-20080090303-A1 Methods and Reagents for Detecting Bioactive Lipids APOLLO ENDOSURGERY, INC. 2008-04-17 US disclosed
US-20070280933-A1 Methods for decreasing immune response and treating immune conditions APOLLO ENDOSURGERY, INC. 2007-12-06 US disclosed
US-20070148168-A1 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions LPATH, INC. 2007-06-28 US disclosed
US-20070148168-A1 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions LPATH, INC. 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075775-A1 TREATMENT OF TRAUMATIC BRAIN INJURY USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID LPAR5, LPAR4, LPAR2 S1PR1 70/4885S1PR4 59/4885S1PR3 87/4885
US-20160168270-A1 PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID LPAR5, LPAR6, LPAR2 S1PR1 177/4885S1PR4 135/4885S1PR3 131/4885
US-20070280933-A1 Methods for decreasing immune response and treating immune conditions LPAR1, LPAR2, S1PR1 S1PR1 3/4885S1PR4 8/4885S1PR3 9/4885
US-20170114125-A1 METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID LPAR5, LPAR2, LPAR6 S1PR1 125/4885S1PR4 118/4885S1PR3 115/4885
US-20080145360-A1 Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders CD47, SGMS1, ALG1 S1PR1 9/4885S1PR4 18/4885S1PR3 15/4885
US-20170088634-A1 TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID LPAR4, LPAR5, LPAR1 S1PR1 72/4885S1PR4 58/4885S1PR3 97/4885
US-20080213274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE S1PR1, S1PR5, S1PR3 S1PR1 1/4885S1PR4 11/4885S1PR3 3/4885
US-20080138334-A1 Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same CD47, ALG1, SGMS1 S1PR1 12/4885S1PR4 20/4885S1PR3 17/4885
US-20090074720-A1 METHODS FOR DECREASING IMMUNE RESPONSE AND TREATING IMMUNE CONDITIONS LPAR1, LPAR2, S1PR1 S1PR1 3/4885S1PR4 8/4885S1PR3 9/4885
US-20070148168-A1 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions S1PR1, S1PR5, S1PR3 S1PR1 1/4885S1PR4 8/4885S1PR3 3/4885
US-20160152735-A1 COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID LPAR2, LPAR3, LPAR5 S1PR1 200/4885S1PR4 159/4885S1PR3 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.